Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (SHA:688505) enrolled the first patient of its phase 2 clinical trial in the US for its hemoporfin injection, according to a Tuesday filing with the Shanghai Stock Exchange.
The drug is indicated for the treatment of port wine stain, a type of birthmark causing a few protrusions comprising countless dilated capillaries, and could occur anywhere in the body, according to the filing.
Shares closed 5% higher in Shanghai during Tuesday's trading.
Price (RMB): ¥6.76, Change: ¥+0.30, Percent Change: +4.64%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments